News for Theravance Biopharma, Inc. (TBPH)

PR NewswireDUBLIN, June 2, 2025 Definitive agreement to result in one-time $225 million cash payment Theravance Biopharma retains rights to up to $150 mill

Theravance Biopharma, Inc. (NASDAQ:TBPH) Q1 2025 Results Conference Call May 8, 2025 5:00 PM ETCompany ParticipantsRick Winningham - Chief Executive...

PR NewswireDUBLIN, May 9, 2025 DUBLIN, May 9, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) toda

Release Date: May 08, 2025For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Theravance Biopha

Refinitiv StreetEvents Event TranscriptE D I T E D V E R S I O NTBPH.OQ - Theravance Biopharma IncQ1 2025 Theravance Biopharma Inc Earnings CallMay 08, 2025 /

PR NewswireDUBLIN, May 8, 2025 YUPELRI® (revefenacin) net sales of $58.3 million, recognized by Viatris, increased 6% versus Q1 20241 TRELEGY net sales of

PR NewswireDUBLIN, April 28, 2025 DUBLIN, April 28, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH

Theravance Biopharma (TBPH) to present key Phase 3 analyses of ampreloxetine at the 2025 International MSA Congress. Focus on potential treatment for neurog

PR NewswireDUBLIN, April 24, 2025 DUBLIN , April 24, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its first quarter 2025 fina

Theravance Biopharma (TBPH) to announce Q1 2025 financial results on May 8, 2025. The company will host a conference call and webcast at 5:00 pm EDT. Repla

Significant Transaction by Madison Avenue Partners, LP (Trades, Portfolio) On March 11, 2025, Madison Avenue Partners, LP (Trades, Portfolio) executed a notable

Despite recent progress, significant risks remain, leading me to stay on the sidelines regarding investment in Theravance. Explore more details here.

DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, today announced the appointment of Renée Galá to its Board of Directors, effective March

Upell Net Sales: Increased 10% year-over-year in Q4 2024, reaching $66.7 million.Full Year Upell Sales: $239 million, with highest profitability since launch.H

Feb 26, 2025 / 10:00PM GMTOperator Ladies and gentlemen, good afternoon. I'd like to welcome everyone to the Theravance Biopharma fourth quarter and full year 2

Theravance Bio (TBPH) delivered earnings and revenue surprises of 0% and 3.50%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

PR NewswireDUBLIN, Feb. 26, 2025 YUPELRI® (revefenacin) US net sales, recognized by Viatris, reached an all-time high of $66.7 million in Q4 2024 and $238

YUPELRI Net Sales: Achieved record US net sales of $66.7 million in Q4 2024, marking a 10% increase year-over-year.Full-Year YUPELRI Sales: Totaled $238.6 mill

Theravance Biopharma Inc (TBPH) is set to release its Q4 2024 earnings on Feb 26, 2025. The consensus estimate for Q4 2024 revenue is $17.09 million, and the ea